GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » Deferred Tax

Hubei Biocause Pharmaceutical Co (SZSE:000627) Deferred Tax : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Hubei Biocause Pharmaceutical Co Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Hubei Biocause Pharmaceutical Co's change in deferred tax for the three months ended in Mar. 2024 was ¥0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0 Mil.

Hubei Biocause Pharmaceutical Co Deferred Tax Historical Data

The historical data trend for Hubei Biocause Pharmaceutical Co's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Pharmaceutical Co Deferred Tax Chart

Hubei Biocause Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hubei Biocause Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hubei Biocause Pharmaceutical Co Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hubei Biocause Pharmaceutical Co Deferred Tax Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Pharmaceutical Co's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Hubei Biocause Pharmaceutical Co (SZSE:000627) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » Deferred Tax
Comparable Companies
SZSE:002423 SHSE:601318 SHSE:601628 HKSE:01299 BOM:543526 MET AFL TSX:MFC PRU SHSE:601601 TPE:2881 TSX:GWO LSE:PRU TPE:2882 TSE:8750 TSX:POW BOM:540719 BOM:540777 SHSE:601336 XKRX:032830
Traded in Other Exchanges
N/A
Address
2nd Floor, Building 1, No. 1 Tianshan Road, Guohua Huijin Center, Zhanghe New District, Hubei Province, Jingmen, CHN, 448000
Website
http://www.tianmaogroup.net
Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.
Executives
Jiang Hai Hua Independent director
Fu Yong Jin Directors, executives
Wu Shi Yan Supervisors

Hubei Biocause Pharmaceutical Co (SZSE:000627) Headlines

No Headlines